Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 06, 2023, titled "Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics".
Zydus Lifesciences Limited Press Release Dec 06 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This product has the potential to be the first FDA-approved treatment for Menkes disease, with ongoing submission processes expected to conclude in the near future. The press release emphasizes the significance of this development for patients suffering from this rare condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 01 2023
- Press Release Nov 10 2023
- Press Release Nov 07 2023
- Press Release Nov 06 2023
- Press Release Nov 03 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Dec 11 2023
- Press Release Dec 14 2023
- Press Release Dec 15 2023
- Press Release Dec 16 2023
- Press Release Dec 22 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences